Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Digital clinical trials

- PMLiVE

BeiGene, Novartis’s PD-1 inhibitor tislelizumab hits the mark in second- or third-line NSCLC

PD-1 inhibitor improved overall survival compared to chemotherapy medication docetaxel

- PMLiVE

FDA approves new self-injection administration for Xolair

Drug is approved for asthma and other allergic and inflammatory conditions

Virtually, the same: Is it time to rethink congress strategy?

In this month’s PME, Jonathan Andrew, Technology Director at Lucid Group discusses the digital transformation that swept through the medcomms industry due to the COVID-19 pandemic. In particular, we saw...

Lucid Group Communications Limited

- PMLiVE

Novartis bolsters radioligand therapy pipeline with new licence agreement

Radioligand therapies are a new potential class of precision oncology drugs

- PMLiVE

Novartis gains EU approval for relapsing MS drug Kesimpta

The drug reduces the number of confirmed relapses in MS patients

Case studies

[CASE STUDIES] Delivering remote access to congress, symposia and enduring materials

See how three pharma companies supported the provision of virtual and on-demand scientific meetings for HCPs during COVID-19.

EPG Health

- PMLiVE

Positive late-stage results for Novartis’ radioligand therapy in advanced prostate cancer

Therapy hit both primary endpoints of overall survival and radiographic progression-free survival

There’s No Going Back: How COVID-19 will Change Pharma Forever

Munther Baara, VP Product Strategy and Innovation at EDETEK, discusses all things clinical trials. Especially, we discuss the current gaps and the impact of COVID-19 on the way Pharma approaches...

Impetus Digital

- PMLiVE

Novartis’ canakinumab misses the mark in previously treated NSCLC

Drug failed to improve survival in previously-treated metastatic NSCLC patients

- PMLiVE

CureVac signs manufacturing agreement with Novartis for COVID-19 vaccine candidate

Novartis will aid manufacturing for up to 50 million doses of CureVac's vaccine in 2021

- PMLiVE

Novartis partners with Bill & Melinda Gates Foundation on ‘accessible’ sickle cell gene therapy

Project will aim to discover and develop a gene therapy for sickle cell disease

Onyx Health Targets Digital Growth with New Executive Director

Healthcare marketing communications agency Onyx Health have appointed Trevor Pill as their new Executive Director

Onyx Health

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links